Bio-Rad Adds New Features to the D-10 Hemoglobin Testing System
HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products today introduces new features of its D-10 Hemoglobin Testing System to better manage patient results, optimize quality control, and more closely match customer workflows and needs.
The D-10 Hemoglobin Testing System offers fully automated diabetes and beta thalassemia testing on a single platform for low to medium volume clinical labs and diabetes clinics. The system measures HbA1c to diagnose and monitor patients living with diabetes, screens for beta thalassemia, and detects abnormal hemoglobins.
"These improvements of the D-10 Hemoglobin Testing System reflect our commitment to A1c and beta thalassemia testing," said Dara Wright, President and EVP of Bio-Rad's Clinical Diagnostic Group. "The enhanced cybersecurity features secure patient information and improved remote support monitoring can reduce downtime in the laboratory."
New Features include:
- Chromatogram export: helps clinicians see potential interferences that may affect the patient's HbA1c results
- On-board QC module: optimizes QC and helps to ensure the reliability of results
- Enhanced cybersecurity features: such as a white listing utility guarantees that only pre-defined programs can run blocking viruses and malware
- Electronic reports: reduces waste and simplify storage and retrieval
For more information about Bio-Rad’s D-10 Hemoglobin Testing System, please visit https://info.bio-rad.com/cdg-d10
BIO-RAD and BIO-RAD D-10 are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Kevin Han, Senior Director
Tina Cuccia, Manager